Literature DB >> 28878017

Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody.

Jon A Kenniston1,2, Brandy M Taylor3, Gregory P Conley2, Janja Cosic2, Kris J Kopacz4, Allison P Lindberg2, Stephen R Comeau2, Kateri Atkins3, Jameson Bullen3, Christopher TenHoor2, Burt A Adelman2, Daniel J Sexton4, Thomas E Edwards3, Andrew E Nixon2.   

Abstract

The neonatal Fc receptor FcRn plays a critical role in the trafficking of IgGs across tissue barriers and in retaining high circulating concentrations of both IgG and albumin. Although generally beneficial from an immunological perspective in maintaining IgG populations, FcRn can contribute to the pathogenesis of autoimmune disorders when an abnormal immune response targets normal biological components. We previously described a monoclonal antibody (DX-2507) that binds to FcRn with high affinity at both neutral and acidic pH, prevents the simultaneous binding of IgG, and reduces circulating IgG levels in preclinical animal models. Here, we report a 2.5 Å resolution X-ray crystal structure of an FcRn-DX-2507 Fab complex, revealing a nearly complete overlap of the IgG-Fc binding site in FcRn by complementarity-determining regions in DX-2507. This overlap explains how DX-2507 blocks IgG binding to FcRn and thereby shortens IgG half-life by preventing IgGs from recycling back into circulation. Moreover, the complex structure explains how the DX-2507 interaction is pH-insensitive unlike normal Fc interactions and how serum albumin levels are unaffected by DX-2507 binding. These structural studies could inform antibody-based therapeutic approaches for limiting the effects of IgG-mediated autoimmune disease.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Fc receptor; antibody; autoimmune disease; immunoglobulin G (IgG); inhibitor; receptor recycling

Mesh:

Substances:

Year:  2017        PMID: 28878017      PMCID: PMC5655520          DOI: 10.1074/jbc.M117.807396

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.

Authors:  W L Martin; A P West; L Gan; P J Bjorkman
Journal:  Mol Cell       Date:  2001-04       Impact factor: 17.970

2.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

3.  An Fc receptor structurally related to MHC class I antigens.

Authors:  N E Simister; K E Mostov
Journal:  Nature       Date:  1989-01-12       Impact factor: 49.962

4.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

5.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

6.  Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn.

Authors:  Adam R Mezo; Kevin A McDonnell; Cristina A Tan Hehir; Susan C Low; Vito J Palombella; James M Stattel; George D Kamphaus; Cara Fraley; Yixia Zhang; Jennifer A Dumont; Alan J Bitonti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-12       Impact factor: 11.205

Review 7.  Targeting complement system to treat myasthenia gravis.

Authors:  Ruksana Huda; Erdem Tüzün; Premkumar Christadoss
Journal:  Rev Neurosci       Date:  2014       Impact factor: 4.353

8.  Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor.

Authors:  Jan Terje Andersen; Bjørn Dalhus; Jason Cameron; Muluneh Bekele Daba; Andrew Plumridge; Leslie Evans; Stephan O Brennan; Kristin Støen Gunnarsen; Magnar Bjørås; Darrell Sleep; Inger Sandlie
Journal:  Nat Commun       Date:  2012-01-03       Impact factor: 14.919

9.  Beta2-microglobulin-deficient mice are resistant to bullous pemphigoid.

Authors:  Z Liu; D C Roopenian; X Zhou; G J Christianson; L A Diaz; D D Sedmak; C L Anderson
Journal:  J Exp Med       Date:  1997-08-29       Impact factor: 14.307

10.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21
View more
  5 in total

Review 1.  The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals.

Authors:  William M Baldwin; Anna Valujskikh; Robert L Fairchild
Journal:  Am J Transplant       Date:  2019-04-15       Impact factor: 8.086

Review 2.  Research progress on neonatal Fc receptor and its application.

Authors:  Mangsha Hu; Shuli Wei; Wuyuan Zhou; Pingli Wang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

Review 3.  Targeting FcRn to Generate Antibody-Based Therapeutics.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Trends Pharmacol Sci       Date:  2018-08-22       Impact factor: 14.819

Review 4.  Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review.

Authors:  Yanis Ramdani; Juliette Lamamy; Hervé Watier; Valérie Gouilleux-Gruart
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

5.  Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses.

Authors:  L J Blumberg; J E Humphries; S D Jones; L B Pearce; R Holgate; A Hearn; J Cheung; A Mahmood; B Del Tito; J S Graydon; L E Stolz; A Bitonti; S Purohit; D de Graaf; K Kacena; J T Andersen; G J Christianson; D C Roopenian; J J Hubbard; A K Gandhi; K Lasseter; M Pyzik; R S Blumberg
Journal:  Sci Adv       Date:  2019-12-18       Impact factor: 14.136

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.